Podnosis The latest on prescription digital therapeutics
4 snips
Nov 19, 2025 
Joseph Perekupka, CEO of Freespira, and Andy Molnar, Senior VP of Industry Affairs for the American Telemedicine Association, dive into the evolving world of prescription digital therapeutics. They discuss the challenges of reimbursement policies and the barriers to adoption these innovative solutions face. The duo also tackles the implications of AI in mental health care, clinician adoption strategies, and the importance of demonstrating ROI and clinical outcomes. Their insights illuminate the future of digital health in a rapidly changing landscape.
AI Snips
Chapters
Transcript
Episode notes
Digital Therapeutics Have Matured
- Digital therapeutics have evolved from a niche concept into diverse clinically validated tools across care management, RPM, and prescription DTx.
- Andy Molnar says digital health fills major care gaps and will remain central to delivering scalable, asynchronous care.
Create A Medicare Benefit For DTx
- Push for a dedicated Medicare benefit category to simplify reimbursement for software-based therapeutics.
- Andy Molnar and Joseph Perekupka argue the Access to Prescription Digital Therapeutics Act would create clearer pathways for payers.
CMS Took A Narrow First Step
- CMS added narrow digital mental health treatment (DMHT) codes as a cautious, testable first step.
- Andy Molnar notes the codes cover a small set of FDA-cleared SAMD products and were intentionally limited to control costs.